The aim of the study was clinical and functional assessment of the effectiveness of the drug "Lutein Ophthalmo" in treatment of age-related macular degeneration . We observed 40 patients (80 eyes ) aged from 55 till 80 years , with the age- related macular degeneration , which were divided into 2 groups. The first group (control ) - 20 people (40 eyes) who received conventional therapy . The second group ( basic) - 20 people ( 40 eyes ) who received conventional treatment in addition to the preparation of 500 mg "Lutein Ophthalmo" leap x 2 times daily for 30 days. During the spent treatment in the basic group of patients visual acuity improvement, reduction relative scotomas and with preservation of a condition of a retina of stable effect is noted indicators. All of this allows us to recommend "Lutein Ophthalmo" in treatment age-related macular degeneration
Age-related macular degeneration (AMD) is one of the leading medical and social problems worldwide. The purpose of this study was to evaluate the effectiveness of drug therapy in patients with early AMD with a lutein-zeaxanthin containing vitamin-mineral complex. The clinical study included 50 patients of the main group who took lutein-zeaxanthin containing a vitamin-mineral complex, 1 capsule once a day for 3 months, for 3 consecutive years, and 50 patients of the control group who did not receive drug therapy. The patients of the main group showed an increase in visual acuity, an improvement in parameters according to OCT data, an improvement in the subjective perception of their own visual functions. At the same time, patients in the control group showed deterioration in visual acuity, progression of the disease according to OCT data, which was manifested by the transition to the next stage of AMD. Conclusion: drug therapy for early stage AMD has a prophylactic effect on the progression of the pathological process in the macular zone.
Age-related macular degeneration (AMD) is one of the leading medical and social problems worldwide. The purpose of this study was to evaluate the effectiveness of drug prevention in patients with early-stage AMD luteinzeaxanthin containing vitamin and mineral complex. The clinical study included 50 patients of the main group who took lutein-zeaxanthin containing a vitamin and mineral complex 1 capsule 1 time a day for 3 months 2 times a year, for 3 consecutive years, and 50 patients of the control group who did not receive drug therapy. In the main group of patients, there was an increase in visual acuity, an improvement in indicators according to OCT data, and an improvement in the subjective perception of their own visual functions. At the same time, the patients of the control group had a deterioration in visual acuity, the progression of the disease according to OCT, which was manifested by the transition to the next stage of AMD. Conclusion: drug therapy of early-stage AMD has a preventive effect on the progression of the pathological process in the macular zone.